[MUSIC PLAYING]
BRADLEY LEIBOVICH: Kidney cancer patients at Mayo Clinic benefit from the best surgical options, the best technology, the best imaging, the best pathology, and clinicians that have expertise and specialize, not just in genitourinary diseases, but specifically in kidney cancer.
R. HOUSTON THOMPSON: We have so many more options today than we did decades ago. The treatments are much safer, much less invasive, and much more effective.
BRIAN COSTELLO: It's a whole-team approach to care within this clinic. And at any given time, we have complete ability to talk to pathologists, to talk to interventional radiologists, to talk to diagnostic radiologists, to talk to radiation oncology. Those are really the key people who we rely on in this space. But the beauty of Mayo Clinic, also, is that it's a multi-specialty integrated practice. So if there is another surgical specialist who needs to get involved, we really have access to those people very quickly.
BRADLEY LEIBOVICH: We have an extremely high-volume practice. We're used to dealing with patients at all stages of disease, from very early to extremely complex multidisciplinary care needs, including integration of systemic therapy with our colleagues in medical oncology, multiple surgical disciplines in addition to urology, and when necessary, radiation oncology or other specialties. It's that multidisciplinary care that allows us to deliver the best outcomes.
R. HOUSTON THOMPSON: Interventional radiology program here at Mayo has really pioneered and led the way in terms of percutaneous ablation for smaller renal tumors.
BRIAN COSTELLO: There's a lot of information about new therapies in terms of systemic therapy from a medical oncology standpoint, including use of immunotherapy, which in first-line treatment has really come on the scene. Just since 2018, we have had five total immunotherapy-based treatments FDA approved in first line.
BRADLEY LEIBOVICH: Because of all the recent changes in how we manage kidney cancer with a proliferation of new drugs, having multiple opinions from a surgical and a medical oncology perspective for each one of our patients has been critically important to us delivering the best care we can.
R. HOUSTON THOMPSON: And it's never been easier to get a second opinion now that video visits are so common.
BRADLEY LEIBOVICH: When you entrust us with your patients, and refer a patient with a complex kidney cancer at a Mayo Clinic, we value your input and guidance in how we care for this patient, and value the partnership that we can develop with you regarding their ongoing care.
[MUSIC PLAYING]
